Vorinostat Patent Expiration
Vorinostat is Used for treating cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL). It was first introduced by Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc
Vorinostat Patents
Given below is the list of patents protecting Vorinostat, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zolinza | US8450372 | Formulations of suberoylanilide hydroxamic acid and methods for producing same | Mar 18, 2028 | Msd Sub Merck |
| Zolinza | US7456219 | Polymorphs of suberoylanilide hydroxamic acid | Mar 11, 2027 | Msd Sub Merck |
| Zolinza | US8093295 | Formulations of suberoylanilide hydroxamic acid and methods for producing the same |
May 16, 2026
(Expired) | Msd Sub Merck |
| Zolinza | US7399787 | Methods of treating cancer with HDAC inhibitors |
Feb 09, 2025
(Expired) | Msd Sub Merck |
| Zolinza | US7851509 | Polymorphs of suberoylanilide hydroxamic acid |
Feb 21, 2024
(Expired) | Msd Sub Merck |
| Zolinza | US7652069 | Polymorphs of suberoylanilide hydroxamic acid |
Mar 04, 2023
(Expired) | Msd Sub Merck |
| Zolinza | US7732490 | Methods of treating cancer |
Mar 04, 2023
(Expired) | Msd Sub Merck |
| Zolinza | US8067472 | Methods of treating Hodgkin's and non-Hodgkin's lymphoma |
Mar 04, 2023
(Expired) | Msd Sub Merck |
| Zolinza | US8101663 | Polymorphs of suberoylanilide hydroxamic acid |
Mar 04, 2023
(Expired) | Msd Sub Merck |
| Zolinza | USRE38506 | Potent inducers of terminal differentiation and methods of use thereof |
Nov 29, 2013
(Expired) | Msd Sub Merck |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Vorinostat's patents.
Latest Legal Activities on Vorinostat's Patents
Given below is the list recent legal activities going on the following patents of Vorinostat.
| Activity | Date | Patent Number |
|---|---|---|
| ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Oct, 2024 | US8450372 |
| Expire Patent Critical
| 01 Jan, 2024 | US8067472 |
| Maintenance Fee Reminder Mailed Critical
| 17 Jul, 2023 | US8067472 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Jun, 2023 | US8093295 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 May, 2022 | US7851509 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Nov, 2021 | US7732490 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Jun, 2021 | US7652069 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Sep, 2020 | US8450372 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 Apr, 2020 | US7456219 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Dec, 2019 | US7399787 |
Vorinostat's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Vorinostat:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
| ||||
| Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer | Institut Claudius Regaud | NA |
TERMINATED
(Sep 1, 2026)
| PHASE1 |
| An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome | Unravel Biosciences, Inc. | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. | City of Hope Medical Center | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE1 |
| The DART DELIVER-02 Study | University of North Carolina, Chapel Hill | NA |
SUSPENDED
(Aug 1, 2026)
| PHASE1 |
| NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab | New Approaches to Neuroblastoma Therapy Consortium | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Vorinostat in Treating Patients With Metastatic Melanoma of the Eye | National Cancer Institute (NCI) | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides | Virogen Biotechnology Inc. | NA |
WITHDRAWN
(May 1, 2026)
| PHASE2 |